An idea of the effect of IL-5 antagonism in severe COVID-19 may be inferred from the results of a small clinical trial that explored granulocyte-macrophage colony-stimulating factor (GM-CSF) antagonism (De Luca et al., 2020). Here, CSF2 is linked to COVID-19.